Regeneron Pharmaceuticals Inc (REGN) stock analysis and fair value
REGN · NASDAQ · Healthcare
795,99 US$
▲ +1,78%
Cerne score
77out of 100
Good
- Quality100
- Growth75
- Financial strength100
- Valuation62
- Dividends36
In 30 seconds
The business. Healthcare. Sells 14,3 B US$ a year, keeps 31% as profit and sales grow 11,0% a year (last 5 years).
Strength. Passes 8 of 8 quality checks and has more cash than debt.
REGN fair value
Work out what the stock is worth with your own growth, margin and return assumptions. Free during launch.
See the fair valueRegeneron Pharmaceuticals Inc key numbers
- Market cap
- 83,5 B US$
- P/E (price ÷ earnings)
- 19,2
- Dividend yield
- 0,43%
- Revenue growth
- 12,8%
- a year, over 9 years
- Profit margin
- 31,4%
- Quality checks
- 8/8
Fiscal 2025 financials, as filed with the SEC.
What analysts say
Buy
26 of 37 analysts recommend buying.
See everything about REGN on Cerne
- Fair value with your own assumptions
- Every analyst and price target
- 10 years of financials in simple charts
- Dividends, earnings and ratios vs. the sector